Effect of pre-emptive analgesia on clinical parameters and tissue levels of TNF-α and IL-1β in third molar surgery: a triple-blind, randomized, placebo-controlled study

Int J Oral Maxillofac Surg. 2017 Dec;46(12):1615-1625. doi: 10.1016/j.ijom.2017.05.007. Epub 2017 Jun 10.

Abstract

This study aimed to evaluate whether pre-emptive analgesia modifies the tissue expression of tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), and whether there is an association with postoperative surgical outcomes. A triple-blind, randomized, placebo-controlled study of patients undergoing mandibular third molar removal was performed. Volunteers were allocated randomly to receive etoricoxib 120 mg, ibuprofen 400 mg, or placebo 1h before surgery. Twenty-four surgical sites per group were required (95% confidence level and 80% statistical power). Pain scores differed significantly between groups (P<0.001). Etoricoxib and ibuprofen reduced pain scores compared to placebo (P<0.05). Pain scores peaked at 4h postoperative in the experimental groups, but at 2h postoperative in the placebo group (P<0.05). A significant reduction in TNF-α concentration from time 0' to time 30' was seen for ibuprofen (P=0.001) and etoricoxib (P=0.016). The ibuprofen group showed a significant reduction in IL-1β levels from time 0' to time 30' (P=0.038). In conclusion, TNF-α and IL-1β levels and the inflammatory events in third molar surgery were inversely associated with the degree of cyclooxygenase 2 selectivity of the non-steroidal anti-inflammatory drugs used pre-emptively. Patients given pre-emptive analgesia showed significant reductions in the clinical parameters pain, trismus, and oedema when compared to the placebo group.

Keywords: IL-1β; TNF-α; inflammatory events; non-steroidal anti-inflammatory drugs; third molar.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Analgesia / methods*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Cross-Over Studies
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Etoricoxib
  • Female
  • Humans
  • Ibuprofen / therapeutic use*
  • Interleukin-1beta / metabolism*
  • Male
  • Molar, Third / surgery*
  • Pain Management / methods*
  • Pain Measurement
  • Pain, Postoperative / prevention & control*
  • Placebos
  • Pyridines / therapeutic use*
  • Sulfones / therapeutic use*
  • Tooth Extraction*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Interleukin-1beta
  • Placebos
  • Pyridines
  • Sulfones
  • Tumor Necrosis Factor-alpha
  • Ibuprofen
  • Etoricoxib